Follitropin
Bemfola, Gonal-f, Ovaleap, Pergoveris (follitropin) is a protein pharmaceutical. Follitropin was first approved as Gonal-f on 1995-10-20. It has been approved in Europe to treat anovulation, assisted reproductive techniques, female infertility, and hypogonadism. The pharmaceutical is active against follicle-stimulating hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| follistim aq | Biologic Licensing Application | 2025-02-03 |
| gonal-f | Biologic Licensing Application | 2025-09-02 |
| gonal-f rff redi-ject | Biologic Licensing Application | 2025-04-03 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
715 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | 26 | 36 | 65 | 90 | 145 | 350 |
| Female infertility | D007247 | EFO_0008560 | N97 | 10 | 6 | 18 | 11 | 40 | 81 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 3 | 3 | 9 | 9 | 33 | 56 |
| Fertilization in vitro | D005307 | — | — | 1 | 3 | 4 | 20 | 9 | 36 |
| Ovulation induction | D010062 | — | — | 3 | 8 | 6 | 9 | 7 | 32 |
| Syndrome | D013577 | — | — | 1 | 2 | 2 | 3 | 21 | 28 |
| Hypogonadism | D007006 | — | E23.0 | 1 | 1 | 4 | 5 | 5 | 16 |
| Healthy volunteers/patients | — | — | — | 6 | 1 | 1 | 1 | 6 | 14 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | 1 | 1 | 8 | 13 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 1 | 1 | 10 | 12 |
Show 32 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 7 | 7 | 1 | — | 22 | 32 |
| Premature menopause | D008594 | — | E28.31 | 5 | 4 | 1 | — | 18 | 24 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 2 | 1 | 1 | — | 9 | 12 |
| Helping behavior | D006379 | — | — | 1 | 2 | 5 | — | 1 | 8 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | 1 | — | 3 | 4 |
| Azoospermia | D053713 | EFO_0000279 | N46.0 | — | — | 1 | — | 3 | 4 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 2 | 1 | — | — | 3 |
| Papillary thyroid cancer | D000077273 | — | — | — | 2 | 1 | — | — | 3 |
| Follicular adenocarcinoma | D018263 | — | — | — | 2 | 1 | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | 1 | — | 1 | 3 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Premature birth | D047928 | EFO_0003917 | O60 | 4 | 3 | — | — | 8 | 12 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | 6 | 7 |
| Menopause | D008593 | EFO_0003922 | N95 | 2 | 2 | — | — | 3 | 6 |
| Male breast neoplasms | D018567 | — | — | 1 | 1 | — | — | 2 | 3 |
| Lymphoma | D008223 | — | C85.9 | 1 | 2 | — | — | 1 | 3 |
| Leiomyoma | D007889 | — | D25 | 1 | 1 | — | — | 1 | 2 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | 2 | — | — | — | 2 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 2 | — | — | — | 2 |
| Insemination | D007314 | — | — | — | 1 | — | — | 1 | 2 |
Show 25 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Therapeutic equivalency | D013810 | — | — | 2 | — | — | — | — | 2 |
| Delayed puberty | D011628 | — | E30.0 | 1 | — | — | — | 1 | 2 |
| Area under curve | D019540 | — | — | 1 | — | — | — | — | 1 |
| Absorption | D000042 | — | — | 1 | — | — | — | — | 1 |
| Precocious puberty | D011629 | — | E22.8 | 1 | — | — | — | — | 1 |
| Asymptomatic diseases | D058070 | — | — | 1 | — | — | — | — | 1 |
| Perimenopause | D047648 | — | — | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Vaccine immunogenicity | D000071497 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 5 | 5 |
| Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 4 | 4 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | — | — | — | — | 4 | 4 |
| Ovarian diseases | D010049 | — | — | — | — | — | — | 3 | 3 |
| Turner syndrome | D014424 | Orphanet_881 | Q96 | — | — | — | — | 3 | 3 |
| In vitro oocyte maturation techniques | D059471 | — | — | — | — | — | — | 3 | 3 |
| Ovarian cysts | D010048 | — | N83.1 | — | — | — | — | 3 | 3 |
| Hypopituitarism | D007018 | EFO_0001380 | E23.0 | — | — | — | — | 3 | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | — | — | — | 3 | 3 |
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | — | 2 | 2 |
Show 136 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Follitropin |
| INN | follitropin alfa |
| Description | Gonadotropin preparations are drugs that mimic the physiological effects of gonadotropins, used therapeutically mainly as fertility medication for ovarian hyperstimulation and ovulation induction. For example, the so-called menotropins consist of LH and FSH extracted from human urine from menopausal women. There are also recombinant variants.
|
| Classification | Protein |
| Drug class | tricyclic compounds; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Target
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
124 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use